Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1394

Sort by

Sort Order Select

Journal Articles

Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 2210.

https://doi.org/10.1182/blood-2019-122272

Published: 2019

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

https://doi.org/10.1182/blood-2019-129422

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

Guillaume Moulis, MD PhD, Manuela Rueter, MSc, Margaux Lafaurie, PharmD, Maryse Lapeyre-Mestre, MD PhD, Carmen investigators Group

Blood (2019) 134 (Supplement_1): 2372.

https://doi.org/10.1182/blood-2019-126000

Published: 2019

Journal Articles

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, MD PhD, Harsh Patel, BS, Vaijayanthi Kandadai Raghavan, Aaron Goodman, Tamara G. Barnes, Razelle Kurzrock, MD

Blood (2019) 134 (Supplement_1): 2319.

https://doi.org/10.1182/blood-2019-126342

Published: 2019

Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Blood (2019) 134 (Supplement_1): 5320.

https://doi.org/10.1182/blood-2019-124102

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia

Shadi Swaidani, MD PhD, Suman Kundu, MBA, Mohamed Samour, MBBS, Bernard Silver, MD, Joseph Parambil, MD, Sonia Thomas, DrPH, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 5761.

https://doi.org/10.1182/blood-2019-127344

Published: 2019

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood (2019) 134 (Supplement_1): 3987.

https://doi.org/10.1182/blood-2019-126044

Published: 2019

Journal Articles

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Guillaume Beziat, Suzanne Tavitian, MD, Sarah Bertoli, MD PhD, Francoise Huguet, MD, Laetitia Largeaud, Francois Vergez, DVM, PhD, Jean-Baptiste Rieu, PharmD, Pierre Bories, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2019) 134 (Supplement_1): 3900.

https://doi.org/10.1182/blood-2019-125782

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Wei Xu, MD PhD, Jie Jin, MD PhD, Keshu Zhou, MD, Li Wang, MD, Huayuan Zhu, Jiejing Qian, Jianying Huang, Fuling Zhou, MD, Xiaohong Xu, Zhiqiang Wang, Wei Guo, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 4000.

https://doi.org/10.1182/blood-2019-126707

Published: 2019

Journal Articles

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

Chan Y. Cheah, Nicholas Wickham, MBBS, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Katharine L Lewis, FRCPath, MRCP, MBBS, Chi-Hung Hui, MBBS, Pek Sang Tang, MBBS, Tejasvi Turpuseema, Hari P Miskin, MSc, Jian-Ping Tang, PhD, Emmanuel Normant, PhD, Alejandro D. Ricart, MD, Constantine S. Tam, MBBS (Hons), MD

Blood (2019) 134 (Supplement_1): 4001.

https://doi.org/10.1182/blood-2019-126951

Published: 2019

Journal Articles

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Ellen K. Ritchie, MD, Sumaiya K. Miah, BA, Sangmin Lee, MD, Tania Curcio, Pinkal Desai, MDMPH, Jeffrey Ball, MD, Michael B. Samuel, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 3858.

https://doi.org/10.1182/blood-2019-130263

Published: 2019

Journal Articles

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Shuhua Yi, MD, Wenjie Xiong, Yi Wang, Rui Lv, Li Zengjun, Wei Liu, Tingyu Wang, An Gang, MD, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4003.

https://doi.org/10.1182/blood-2019-130133

Published: 2019

Journal Articles

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 4050.

https://doi.org/10.1182/blood-2019-127155

Published: 2019

Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4085.

https://doi.org/10.1182/blood-2019-129347

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Eltrombopag for Immune Thrombocytopenia Adult Patients in the Real-Life Practice in France. Interim Results of the Elextra Study

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only